Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866308 | 0.98 | DPP4 (0.58) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL6208426 | 0.90 | SLC6A4 (0.64) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL6208549 | 0.88 | SLC6A4 (0.61) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL5365797 | 0.85 | HSD11B1 (0.72) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11526870 | 0.84 | HSD11B1 (0.70) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL977926 | 0.83 | HSD11B1 (0.69) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL17761201 | 0.83 | HSD11B1 (0.51) | HSD11B1SLC6A4L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL3545674 | 0.83 | HSD11B1 (0.47) | DPP4HSD11B1LMNASLC6A4L3MBTL1 | |
| SCHEMBL6491320 | 0.83 | HSD11B1 (0.51) | HSD11B1LMNASLC6A4L3MBTL1SLC6A2 | |
| SCHEMBL12836593 | 0.83 | SLC6A3 (0.62) | HSD11B1SLC6A4SLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | DPP4 1957/4885HSD11B1 1180/4885LMNA 1000/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | DPP4 1957/4885HSD11B1 1180/4885LMNA 1000/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | DPP4 2037/4885HSD11B1 1367/4885LMNA 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.